ADPT
Adaptive Biotechnologies Corporation · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +10.5% ·
share flow +1.3% ·
net new positions +9.5%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | -1 | 18.90K | $493,205 | n/a | −1 |
| Q2 2026 | 106 | 0 | 115.12M | $2.47B | +6 | −7 |
| Q1 2026 | 110 | +7 | 111.61M | $1.55B | +11 | −4 |
| Q4 2025 | 102 | 0 | 114.72M | $1.86B | +1 | −1 |
| Q3 2025 | 21 | +2 | 74.70M | $1.12B | +2 | n/a |
| Q2 2025 | 16 | +2 | 70.34M | $819.50M | +2 | n/a |
| Q1 2025 | 11 | 0 | 46.91M | $348.49M | +2 | −2 |
| Q4 2024 | 11 | -1 | 53.01M | $317.80M | n/a | −1 |
| Q3 2024 | 11 | +2 | 55.08M | $282.02M | +2 | n/a |
| Q2 2024 | 9 | n/a | 54.39M | $196.88M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Viking Global Investors ✦ | 29.99M | 0.0% | $448.71M | 1.2% | Held | 6 | SEC ↗ |
| 2 | BlackRock ✦ (passive) | 13.36M | -2.3% | $199.84M | 0.0% | ▼ Trim | 2 | SEC ↗ ×15 |
| 3 | The Vanguard Group ✦ (passive) | 11.28M | 0.0% | $168.68M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 4 | Geode Capital Management ✦ (passive) | 3.40M | +5.8% | $50.89M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 5 | ARK Investment Management ✦ | 3.17M | -21.2% | $47.36M | 0.3% | ▼ Trim | 6 | SEC ↗ |
| 6 | State Street Global Advisors ✦ (passive) | 3.08M | +1.7% | $46.07M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Arrowstreet Capital ✦ | 2.44M | +544.0% | $36.52M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Goldman Sachs Group ✦ | 1.88M | n/a | $28.12M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 9 | T. Rowe Price ✦ | 1.09M | +790.1% | $16.27M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 10 | Morgan Stanley ✦ | 1.07M | n/a | $16.04M | 0.0% | n/c | 1 | SEC ↗ ×9 |
| 11 | D. E. Shaw & Co. ✦ | 738.18K | +21.4% | $11.04M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 609.00K | +40.8% | $9.11M | 0.0% | ▲ Add | 6 | SEC ↗ ×5 |
| 13 | Wellington Management ✦ | 501.08K | New | $7.50M | 0.0% | New | 1 | SEC ↗ ×2 |
| 14 | JPMorgan Chase ✦ | 471.34K | n/a | $7.05M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 15 | Millennium Management ✦ | 397.31K | -60.8% | $5.94M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 16 | Fidelity (FMR) ✦ | 324.50K | +11.5% | $4.85M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 17 | Point72 Asset Management ✦ | 319.47K | -76.8% | $4.78M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 18 | Renaissance Technologies ✦ | 279.70K | +460.5% | $4.18M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 19 | Bridgewater Associates ✦ | 151.25K | New | $2.26M | 0.0% | New | 1 | SEC ↗ |
| 20 | Gotham Asset Management ✦ | 127.06K | +76.8% | $1.90M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 21 | Citadel Advisors ✦ | 28.08K | -96.5% | $420,137 | 0.0% | ▼ Trim | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Wellington Management | $7.50M | 0.0% |
| Bridgewater Associates | $2.26M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 295 holders, 151.59M shares, $2.01B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 300 sh · $7,635
Officer · 11.58K sh · $280,376
Officer · 11.88K sh · $304,272
Officer · 5.10K sh · $131,682
Officer · 6.78K sh · $173,390
Officer · 11.88K sh · $302,966
Officer · 9.18K sh · $232,738
Officer · 2.70K sh · $70,389
Officer · 11.88K sh · $313,777
Officer · 11.88K sh · $304,866
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology